If you have been reading about circadian rhythm and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
== Discussion == Cosmetic surgery providers often advise their patients that many options now exist for improving the appearance of the lips. Most practitioners also admit that successful lip augmentation is highly dependent on the skill of the provider, with that skill stemming from many years of experience injecting the lips of many types of patients. Moreover, the surgeon must master various injection techniques. With many injectables, the benefit to the patient is an immediate return to normal, usual activities. A few surgeons offer a procedure known as surgical flap augmentations, in which small sections of skin near the lips or inside the mouth are excised and added to the lips. This technique does not add volume and achieves only a slight outward protrusion of the lips.
Corneal epithelium: an exceedingly thin multicellular epithelial tissue layer (non-keratinized stratified squamous epithelium) of fast-growing and easily regenerated cells, kept moist with tears. Irregularity or edema of the corneal epithelium disrupts the smoothness of the air/tear-film interface, the most significant component of the total refractive power of the eye, thereby reducing visual acuity. Corneal epithelium is continuous with the conjunctival epithelium, and is composed of about 6 layers of cells which are shed constantly on the exposed layer and are regenerated by multiplication in the basal layer. Bowman's layer (also known as the anterior limiting membrane): when discussed in lieu of a subepithelial basement membrane, Bowman's Layer is a tough layer composed of collagen (mainly type I collagen fibrils), laminin, nidogen, perlecan and other HSPGs that protects the corneal stroma. When discussed as a separate entity from the subepithelial basement membrane, Bowman's Layer can be described as an acellular, condensed region of the apical stroma, composed primarily of randomly organized yet tightly woven collagen fibrils. These fibrils interact with and attach onto each other. This layer is eight to 14 micrometres (μm) thick and is absent or very thin in non-primates. Corneal stroma (also substantia propria): a thick, transparent middle layer, consisting of regularly arranged collagen fibers along with sparsely distributed interconnected keratocytes, which are the cells for general repair and maintenance. They are parallel and are superimposed like book pages.
== Reception == The level's originality and tonal shift caused it to stand out to critics. GamesRadar+ journalist Alex Avard praised "We Don't Go To Ravenholm..." as an example of a horror sequence in a non-horror game, describing it as "harrowing" and a "blood-soaked frightfest". Fellow GamesRadar+ journalist Ashley Reed praised the game's inclusion of "Zombie Chopper", an achievement which forced the player to beat the entire level employing only the Gravity Gun, arguing that not using weapons forced them to think creatively about how to proceed through the level, turning to items such as saw blades as improvised weaponry and employing strategies such as fleeing the zombies before they could notice the character's presence. The level was also praised for its effective use of horror elements. Den of Geek journalist Matthew Byrd described Ravenholm as "the perfect horror level", stating that it both served as a send up of horror tropes and effectively utilized them to scare the player. Suggesting that it "just happened to be the perfect idea released at the perfect time", Byrd further stated that some elements of the level "certainly don't feel quite as groundbreaking" 15 years later as they did upon the game's release. PC Gamer journalist Andy Kelly included the game on the list of his best first-person shooter levels ever, calling it "a tense, terrifying gauntlet" and "probably the best level Valve has ever designed". Screen Rant journalist Padraig Cotter argued that the level was "arguably the game's most famous" and had a "perfect balance" of horror and action.
On 29 March, Trump stated that he would prefer to "take the oil in Iran". He proposed taking Iran's oil export center, Kharg Island, claiming that the United States could capture the territory "very easily", and implying that the US could occupy it for some time. On 30 March, Trump said that if a deal were not reached soon and the Strait of Hormuz reopened, the US would strike all of Iran's power plants, oil wells, Kharg Island, and possibly all its desalinization plants, although the feasibility and strategic value of some of Trump's threats were contested. On the same day Turkey and NATO intercepted the fourth missile directed towards Turkish territory. Iran denied firing a missile at Turkey, claiming that it was a false flag attack. The US began flying B-52 bombers over Iranian territory for the first time, indicating its confidence of air supremacy over Iran. The US used bombers to target an ammunition depot and air base in Isfahan, causing large explosions. U.S-allied Gulf states such as Saudi Arabia, the UAE, Kuwait, and Bahrain reportedly pushed Trump to continue the war until there are significant changes in Iran's leadership. American journalist Shelly Kittleson was kidnapped in Baghdad by Kata'ib Hezbollah—the strongest faction within the PMF—who demanded that the Iraqi government release several detained members of the group. On 1 April, Mehr News Agency, a semi-official Iranian government news outlet, reported that policy expert and former foreign minister Kamal Kharazi was seriously injured and his wife was killed in an airstrike which hit his home.
Sources: en.wikipedia.org
=== Classifications === Cystoceles can be further described as being apical, medial, or lateral. Apical cystocele is located upper third of the vagina. The structures involved are the endopelvic fascia and ligaments. The cardinal ligaments and the uterosacral ligaments suspend the upper vaginal-dome. The cystocele in this region of the vagina is thought to be due to a cardinal ligament defect. Medial cystocele forms in the mid-vagina and is related to a defect in the suspension provided by a sagittal suspension system defect in the uterosacral ligaments and pubocervical fascia. The pubocervical fascia may thin or tear and create the cystocele. An aid in diagnosis is the creation of a 'shiny' spot on the epithelium of the vagina. This defect can be assessed by MRI. Lateral cystocele forms when the pelviperineal muscle and its ligamentous–fascial develop a defect. The ligamentous– fascial creates a 'hammock-like' suspension and support for the lateral sides of the vagina. Defects in this lateral support system result in a lack of bladder support. Cystocele that develops laterally is associated with an anatomic imbalance between anterior vaginal wall and the arcus tendineus fasciae pelvis – the essential ligament structure.
are the respective mole fractions and viscosities of the component liquids. Since blending is an important process in the lubricating and oil industries, a variety of empirical and proprietary equations exist for predicting the viscosity of a blend.
Hertz (1939), operations research scholar known for pioneering the Monte Carlo methods in finance Victor Wouk (1939), pioneer in the development of electric and hybrid vehicles Julius Ashkin (1940), nuclear physicist, brother of Arthur Ashkin '47 Jeremiah Stamler (1940), epidemiologist, expert in the field of preventive cardiology, professor emeritus at Northwestern University Ulrich P. Strauss (1941), chemist at Rutgers University, 1971 Guggenheim Fellow Bruce Wallace (1941), geneticist, professor at Virginia Tech Robert S. Wallerstein (1941), psychoanalyst and former president of the International Psychoanalytical Association and director of the Langley Porter Psychiatric Institute, brother of political scientist Immanuel Wallerstein '51 Kimball Chase Atwood III (1942), geneticist, professor at Columbia University Medical School Leon Davidson (1942), chemical engineer known for his work in the Manhattan Project and the study of Unidentified Flying Objects Karl Koopman (1943), chiropterologist and curator at the American Museum of Natural History Robert G.
That same year, Sonic Healthcare acquired 56% ownership of the Schottdorf Group in Germany, 72% ownership of the Independent Practitioner Network Limited (IPN), the pathology operations of Endeavour HealthCare in NSW and WA merging them into Douglass Hanly Moir Pathology and Clinipath Pathology, and (through IPN) Endeavour's medical centre operations. In 2005, Sonic Healthcare acquired an 82% interest in Clinical Pathology Laboratories, Inc., the largest privately owned regional pathology laboratory in the United States.
The use of N-hydroxyphthalimide as a catalyst in the oxidation of KA oil avoids the formation of the undesirable by-product ammonium sulfate which is produced by the conventional ε-caprolactam synthesis (Beckmann rearrangement of cyclohexanone oxime with sulfuric acid). Alkanes are converted into nitroalkanes in the presence of nitrogen dioxide.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.